Background
==========

Telomerase, an enzyme related to cellular immortality, stabilizes telomere length by adding DNA repeats onto telomere ends \[[@B1],[@B2]\]. Many studies have revealed that telomerase activity is expressed in many different types of carcinomas, detected in more than 85% of the human carcinoma samples, and it has been found to be useful as a prognostic indicator \[[@B3]-[@B5]\]. Telomerase activity is mainly regulated by human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of telomerase \[[@B6],[@B7]\]. Also, hTERT has been significantly detected in many types of sarcoma samples, and previous reports have indicated that hTERT expression is associated with tumor aggressiveness, feature and clinical outcome in sarcomas \[[@B8]-[@B14]\]. Therefore, hTERT may play an important role in telomere maintenance mechanisms in human sarcomas. However, it is notable that thus far, there has been no clear understanding of the mechanisms of hTERT expression especially in sarcomas. p38 is a mitogen-activated protein kinase (MAPK) activated by phosphorylation on serine/threonine residue when cells are exposed to cellular stress, and has a wide variety of biological functions \[[@B15]-[@B17]\]. Recent studies have suggested that signals transmitted through MAP kinase can increase or decrease hTERT transcription in response to various stimuli, depending on the downstream mediators \[[@B18]-[@B22]\]. This study was undertaken to analyze the clinical significance of p38 MAPK and hTERT expression in primary tumor samples from soft tissue malignant fibrous histiocytomas (MFH), liposarcomas (LS) and bone MFH patients. In addition, with the broader aim of discovering regulation factors of hTERT in sarcomas, we investigated whether there is a correlation between hTERT and p38 MAPK.

Methods
=======

Patients and tumor samples
--------------------------

A total of 69 (36 soft tissue MFHs, 24 LSs and 9 bone MFHs) sarcoma samples were obtained at the time of surgery, were immediately frozen and stored at -80°C until commencement of our study. Summarized clinical data at the time of last observation are shown in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. All patients with these sarcomas were treated with tumor resection and/or chemotherapy between 1988 and 2005. We performed brachytherapy or external radiation therapy following conservative surgery for all soft tissue sarcoma patients who received marginal resection. Chemotherapy comprised of multiagent systemic chemotherapy in metastatic patients. High dose ifosfamide, doxorubicin and/or cisplatin were used. We collected all primary tumor samples by tumor resection or biopsy, and no patients had undergone chemotherapy before surgical specimens were collected. The study was approved by our institutional review board (Dai eki 133, and 263).

###### 

Data in 36 patients with soft tissue MFH

  Age (Yrs)   Gender   Site        Histol. Type   Prognosis   Period (mos.)   hTERT    p38
  ----------- -------- ----------- -------------- ----------- --------------- -------- ------
  53          Male     thigh       stori-pleo     DOD         12              28.4     0
  48          Male     thigh       myxoid         NED         80              1564.5   0
  76          Female   thigh       stori-pleo     DOD         22              2365     8.7
  54          Male     thigh       stori-pleo     DOD         12              978.4    6.1
  49          Male     upper arm   stori-pleo     DOD         18              22       2.8
  63          Female   axillary    myxoid         CDF         28              383.4    4.5
  82          Male     thigh       stori-pleo     CDF         80              181.9    3.3
  66          Female   thigh       stori-pleo     CDF         60              133.2    0
  75          Male     thigh       stori-pleo     NED         35              1986.5   2.8
  45          Female   inguinal    myxoid         CDF         27              8.5      0.3
  78          Female   thigh       stori-pleo     DOD         9               8.9      5.2
  35          Male     thigh       stori-pleo     CDF         52              1.9      2.1
  81          Male     thigh       stori-pleo     CDF         26              0        0
  84          Male     buttock     stori-pleo     CDF         26              45.9     10
  57          Female   shoulder    stori-pleo     CDF         62              158.3    36.2
  76          Female   thigh       stori-pleo     DOD         6               196.8    50.1
  75          Male     thigh       stori-pleo     DOD         10              147.3    15.6
  57          Male     thigh       stori-pleo     CDF         94              696.5    14.1
  69          Male     thigh       stori-pleo     CDF         94              18       60.3
  72          Male     thigh       stori-pleo     DOD         49              0        0.3
  64          Female   buttock     myxoid         DOD         10              2.6      10.3
  55          Female   thigh       myxoid         DOD         21              1029.5   23
  59          Female   shoulder    stori-pleo     DOD         47              2656     71.1
  74          Male     thigh       myxoid         DOD         27              15.6     0.4
  59          Female   lower leg   inflammatory   CDF         115             4.6      1.7
  46          Male     thigh       stori-pleo     CDF         98              0        0
  73          Male     thigh       stori-pleo     CDF         112             0        0
  62          Female   forearm     myxoid         CDF         138             145.3    5
  59          Female   thigh       stori-pleo     DOD         7               45.3     1.3
  49          Male     upper arm   stori-pleo     CDF         87              10.1     0
  85          Male     thigh       stori-pleo     CDF         106             0.9      0.2
  58          Female   buttock     stori-pleo     DOD         6               103.8    0.1
  73          Male     thigh       stori-pleo     CDF         112             145.3    0
  78          Male     lower leg   stori-pleo     CDF         119             125.1    0.2
  71          Female   lower leg   myxoid         NED         65              31.9     2.4
  73          Female   lower leg   myxoid         CDF         25              135.6    7.8

stori-pleo = storiform-pleomorphic type

CDF = continuously disease-free

NED = no evidence of disease

DOD = died of disease

###### 

Data in 24 patients with liposarcoma

  Age (Yrs)   Gender   Site        Histol. Type   Prognosis   Period (mos.)   hTERT   p38
  ----------- -------- ----------- -------------- ----------- --------------- ------- ------
  65          Male     thigh       myxoid         NED         93              4       0.4
  35          Female   popliteal   myxoid         CDF         108             31.6    1
  50          Female   thigh       myxoid         CDF         102             0       0.4
  42          Male     shoulder    myxoid         CDF         41              726.6   30.1
  65          Male     thigh       myxoid         CDF         56              484.9   38.2
  66          Female   thigh       dediff.        CDF         66              271.8   0.2
  47          Female   thigh       myxoid         CDF         84              117.5   21.1
  58          Male     thigh       myxoid         CDF         76              331.9   0.5
  74          Male     thigh       myxoid         DOD         27              148.7   11.2
  60          Male     thigh       pleomorphic    CDF         132             145     0.4
  51          Male     thigh       pleomorphic    CDF         31              3.1     1.4
  66          Male     upper arm   myxoid         CDF         70              29.5    0.7
  69          Male     thigh       myxoid         DOD         13              331.2   14
  41          Male     lower leg   myxoid         CDF         51              0.8     1.8
  47          Male     forearm     dediff.        DOD         12              435.8   2
  62          Female   thigh       myxoid         CDF         62              76.5    0.6
  68          Male     thigh       myxoid         CDF         100             97.5    1.1
  73          Female   buttock     myxoid         DOD         14              391.8   31.6
  48          Female   forearm     myxoid         CDF         132             0       1.9
  52          Female   thigh       myxoid         CDF         85              91.3    0
  48          Male     thigh       myxoid         DOD         15              94.3    0.7
  60          Female   thigh       myxoid         CDF         85              58.7    2
  36          Male     thigh       myxoid         CDF         81              46.8    0.9
  56          Male     thigh       myxoid         CDF         69              191.6   1.2

defiff. = dedifferentiated CDF = continuously disease-free

DOD = died of disease

###### 

Data in 9 patients with bone MFH

  Age (Yrs)   Gender   Site       Histol. Type   Prognosis   Period (mos.)   hTERT    p38
  ----------- -------- ---------- -------------- ----------- --------------- -------- -------
  23          Female   femur      stori-pleo     CDF         130             304      0
  65          Female   femur      stori-pleo     DOD         37              1405.4   191.1
  46          Male     femur      stori-pleo     CDF         141             921.8    36.2
  27          Female   clavicle   stori-pleo     CDF         92              323.1    10.3
  57          Male     femur      stori-pleo     CDF         93              241.7    0
  69          Male     femur      stori-pleo     DOD         8               1278.2   60.3
  67          Male     sacrum     stori-pleo     DOD         7               324.5    35.2
  38          Male     humerus    stori-pleo     DOD         18              603.6    49.3
  57          Female   ilium      stori-pleo     DOD         6               326.5    35

stori-pleo = storiform-pleomorphic type

CDF = continuously disease-free

DOD = died of disease

Quantification of hTERTand p38 MAPK mRNA expression
---------------------------------------------------

Total cellular RNA was extracted using a Rneasy Mini Kit (Qiagen, Valencia, CA), and cDNA was synthesized using 1 μg of total RNA using a Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany). Quantitative detection of hTERT mRNA and p38 MAPK was performed with the LightCycler TaqMan Master using the LightCycler instrument (Roche Molecular System, Alameda, CA). The primer pairs 5\'-CGGAAGAGTGTCTGGAGCAA-3\' and 5\'-GGATGAAGCGGAGTCTGGA-3\' for hTERT, and 5\'-ATGCCGAAGATGAACTTTGC-3\' and 5\'-TCTTATCTGAGTCCAATACAAGCATC-3\' for p38 MAPK were used for amplification. PCR used 10 seconds at 95°C, 30 seconds at 60°C and 1 second at 72°C with 45 cycles. Expression of the gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also analyzed in each tumor sample as an indicator of RNA quality. A 3 × 10^6^of HeLa cell was used as a positive control. Quantification of mRNA expression was indicated by measuring mRNA expression levels of hTERT or p38 MAPK/mRNA levels of the Hela cell ratio.

Statistical analysis
--------------------

The cumulative prospective of overall survival was calculated using the method of Kaplan-Meier. Statistical significance of the differences between the survival curves was evaluated using the log-rank test. Pearson\'s product-moment correlation coefficient (r and p values) was used to study the relationship between p38 MAPK and hTERT. Data are presented as the mean ± SD. In all analyses, a p value of \< 0.05 was considered to indicate significance.

Results
=======

Overall results of 69 samples
-----------------------------

### p38 MAPK and hTERT mRNA expression

p38 MAPK expression was demonstrated in 84.1% (58 of 69) and hTERT mRNA expression was demonstrated in 91.3% (63 of 69) of all 69 samples. The levels of p38 MAPK were 13.4 ± 27.7 (range: 0-191.1) and those of hTERT were 336.5 ± 554.8 (range: 0-2656.0) in all samples. We previously reported the data of hTERT in bone and soft tissue MFHs \[[@B23],[@B24]\].

### Correlation between levels of p38 MAPK and hTERT mRNA expression

There was a significant correlation between the values of p38 MAPK expression and hTERT, with increased p38 MAPK expression with higher hTERT in all samples (r = 0.445, p = 0.0001) (Figure [1](#F1){ref-type="fig"}).

![**Correlation between p38 and hTERT in all samples**. There was a significant correlation between the values of p38 expression and those of hTERT, with increased p38 expression with higher hTERT in all samples (r = 0.445, p = 0.0001).](1756-9966-31-5-1){#F1}

### Prognostic factors

Patients who had a higher than average expression of p38 MAPK had a significantly worse prognosis (5-year survival rate; 38.1%) than other patients overall (73.8%) (p = 0.0036) (Figure [2](#F2){ref-type="fig"}). There were no significant differences in prognosis between patients who had a higher than average expression of hTERT (5-year survival rate: 38.6%) and those who did not (71.1%) (p = 0.0585).

![**Kaplan-Meier analysis of the association between the survival and the p38 in all samples**. Patients who had a higher than average expression of p38 MAPK had a significantly worse prognosis (5-year survival rate; 38.1%) than other patients (73.8%) overall (p = 0.0036).](1756-9966-31-5-2){#F2}

Soft tissue MFH samples
-----------------------

### p38 MAPK and hTERT mRNA expression

p38 MAPK expression was demonstrated in 77.8% (28 of 36) and hTERT mRNA expression was demonstrated in 88.9% (32 of 36) of soft tissue MFH samples. The levels of p38 MAPK were 9.60 ± 17.5 (range: 0-71.1) and those of hTERT were 371.6 ± 695.9 (range: 0-2656.0).

### Correlation between levels of p38 MAPK and hTERT mRNA expression

There was a significant correlation between the values of p38 MAPK expression and hTERT, with increased p38 MAPK expression with higher hTERT in soft tissue MFH samples (r = 0.352, p = 0.0352) (Figure [3](#F3){ref-type="fig"}).

![**Correlation between p38 and hTERT in soft tissue MFH samples**. There was a significant correlation between the values of p38 expression and those of hTERT (r = 0.352, p = 0.0352).](1756-9966-31-5-3){#F3}

### Prognostic factors

There were no significant differences in prognosis between patients who had a higher than average expression of p38 MAPK (5-year survival rate: 41.7%) and those who did not (65.0%) (p = 0.213). There were no significant differences in prognosis between patients who had a higher than average expression of hTERT (41.7%) and those who did not (62.7%) (p = 0.610).

Liposarcoma samples
-------------------

### p38 MAPK and hTERT mRNA expression

p38 MAPK expression was demonstrated in 95.8% (23 of 24) and hTERT mRNA expression was demonstrated in 91.7% (22 of 24) of LS samples. The levels of p38 MAPK were 6.81 ± 11.5 (range: 0-38.2) and those of hTERT were 171.3 ± 189.9 (range: 0-726.6) in LS samples.

### Correlation between levels of p38 MAPK and hTERT mRNA expression

There was a significant correlation between the values of p38 MAPK expression and hTERT, with increased p38 MAPK expression with higher hTERT in LS samples (r = 0.704, p = 0.0001) (Figure [4](#F4){ref-type="fig"}).

![**Correlation between p38 and hTERT in liposarcoma samples**. There was a significant correlation between the values of p38 expression and those of hTERT (r = 0.704, p = 0.0001).](1756-9966-31-5-4){#F4}

### Prognostic factors

Patients who had a higher than average expression of p38 MAPK (5-year survival rate: 50.0%) had a significantly worse prognosis than other patients (88.9%) (p = 0.0448) in LS patients. There were no significant differences in prognosis between patients who had a higher than average expression of hTERT (62.5%) and those who did not (87.5%) (p = 0.110).

Bone MFH samples
----------------

### p38 MAPK and hTERT mRNA expression

p38 MAPK expression was demonstrated in 77.8% (7 of 9) and hTERT expression was demonstrated in all (9 of 9) of bone MFH samples. The levels of p38 MAPK were 46.4 ± 58.2 (range: 0-191) and the levels of hTERT were 636.5 ± 453.3 (range: 241.7-1405.4) in bone MFH samples.

### Correlation between levels of p38 MAPK and hTERT mRNA expression

There was a significant correlation between the values of p38 MAPK expression and hTERT, with increased p38 MAPK expression with higher hTERT (r = 0.802, p = 0.0093) (Figure [5](#F5){ref-type="fig"}).

![**Correlation between p38 and hTERT in bone MFH samples**. There was a significant correlation between the values of p38 expression and those of hTERT (r = 0.802, p = 0.0093).](1756-9966-31-5-5){#F5}

### Prognostic factors

Patients who had a higher than average expression of p38 MAPK (5-year survival rate: 0%) had a worse prognosis than other patients (66.7%), but did not reach significant differences (p = 0.202). There were no significant differences in prognosis between patients who had a higher than average expression of hTERT (33.3%) and those who did not (50.0%) (p = 0.904).

Discussion
==========

hTERT is the catalytic telomerase subunit component that copies a template region of its functional RNA subunit to the end of the telomere. In terms of carcinomas, hTERT mRNA expression and telomerase activity are closely associated, and quantification of hTERT mRNA has been reported as an alternative to the measure of telomerase activity \[[@B7],[@B25],[@B26]\]. Also, in sarcomas, the correlation between telomerase activity and hTERT has been reported \[[@B9],[@B10],[@B27]\]. However, in contrast, previous reports maintained that hTERT expression does not correlate to telomerase activity \[[@B12],[@B23]\], and hTERT mRNA expression was only studied in the absence of detectable telomerase activity on sarcomas \[[@B8],[@B12],[@B27],[@B28]\]. There is no clear understanding of the discordance between hTERT and telomerase activity in sarcomas \[[@B23],[@B29]\]. Recently, the presence of telomerase activity and alternative lengthening of telomeres (ALT) in several sarcomas was examined extensively, and these studies indicate a positive correlation between the telomere maintenance mechanism and tumor aggressiveness in several sarcoma types \[[@B29]\]. Furthermore, a positive correlation between hTERT and tumor aggressiveness in several sarcomas has been reported \[[@B8]-[@B14]\]. Therefore, it could be necessary to analyze hTERT, in order to elucidate the telomere maintenance mechanisms and the tumorigenesis of sarcomas.

The predominence of large numbers of protein kinases involved in signal cascades following genotoxic stress is the p38 MAPK \[[@B30]\]. p38 MAPK is shown to induce a wide variety of intracellular responses, with roles in tumorigenesis, cell-cycle regulation, development, inflammation and apoptosis \[[@B15]-[@B17]\]. Recent studies have suggested that signals transmitted through MAP kinase can regulate hTERT transcription. Epidermal growth factor (EGF) affects the up-regulation of hTERT transcription through the MAP kinase cascades \[[@B20]\]. E26 transformation-specific (Ets) transcription factors, downstream of the mitogen signaling pathways of MAP kinase, regulates hTERT \[[@B31]\]. p38 MAPK may play an important role in the activation of the hTERT promoter by the upstream stimulatory factor (USF) in tumor cells \[[@B32]\]. In the present study, there was a significant positive correlation between the values of p38 MAPK expression and hTERT, with increased p38 MAPK expression with higher hTERT in sarcoma samples. This is the first report to show a correlation between the levels of hTERT mRNA expression and the levels of p38 MAPK in human sarcomas, and these results may suggest that p38 MAPK plays a role in up-regulation of hTERT in soft tissue MFH, liposarcomas, and bone MFH, while we do not have a clear understanding if some factor regulates both p38 MAPK and hTERT expression.

Recent studies have demonstrated that p38 MAPK has diverse roles in the pathogenesis of several cancers and have shown that they are also involved in regulating other functions including the differentiation and proliferation of various cell types \[[@B33]\]. The p38 MAPK pathway is most frequently associated with a tumor suppressor function, based on its negative regulation of proliferation and survival of cells \[[@B33],[@B34]\]. However, contradictory effects have been observed, a fact that points to the pathway playing a positive role in cell-cycle progression in some carcinoma cells \[[@B35]-[@B37]\]. In terms of sarcoma cells, inhibition of p38 MAPK activity rescues the antitumor agent fenretinide-mediated cell death in Ewing\'s sarcoma family of tumors \[[@B38]\], and inhibition of p38 signals results showing a significant reduction in chondrosarcoma cell proliferation mediated by complex effects of p38 signaling on cell-cycle gene expression \[[@B39]\], which suggests that p38 MAPK may play an important role in tumorigenesis in these sarcomas. In the clinical setting, p38 MAPK expression correlates to poor prognosis (p = 0.0036) in overall patients; of high expression of p38 MAPK, indicating the likelihood of a poor outcome and may indicate a positive role of p38 MAPK in tumor proliferation and aggressiveness, in patients with sarcomas. In terms of bone and soft tissue MFH, there were no significant differences in prognosis between patients who had a higher than average expression of p38 MAPK and those who did not. However, patients who had above average p38 (5-year survival rate: soft tissue MFH; 41.7%, bone MFH; 0%) had a worse prognosis than other patients (5-year survival rate: soft tissue MFH; 65.0%, bone MFH; 66.7%), but did not reach significant differences. These results may be due to small numbers of patients. Patients who had a higher than average expression of p38 MAPK (5-year survival rate: 50.0%) had a significantly worse prognosis than other patients (88.9%) (p = 0.0448) in LS patients. Therefore, high expression of p38 MAPK may correlate with a worse prognosis especially for LS patients.

Conclusions
===========

p38 MAPK may be a useful marker in the assessment of hTERT and prognosis. Given that more than 80% of sarcomas express p38 MAPK and hTERT, elucidation of the pathways and target genes of p38 MAPK in sarcomas will yield additional understandings into the pathogenesis of several sarcomas and may lead to novel therapeutic strategies for their treatment.
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